Abstract 5501
Background
Head and neck squamous cell carcinoma (HNSCC) patients with a significant tobacco smoking history have a poor prognosis compared to never smokers. We hypothesize the poor prognosis in tobacco smokers with HNSCC is, at least in part, due to ongoing suppression of immune response and that understanding of deregulated signals in each step may provide insights to improve clinical outcomes of HNSCC patients.
Methods
We characterized the tumor immune microenvironment (TIM) of HNSCC in a retrospective cohort of 177 current, former, and never smokers. Tumors were subjected to analysis of CD3, CD8, FOXP3, PD-1, PD-L1, and pan-cytokeratin by multiplex immunofluorescence, whole exome sequencing, and RNA sequencing. The immune markers were measured in the tumor core (TC), tumor margin (TM), and stroma (S).
Results
Our data indicate that current smokers have significantly lower numbers of CD8+ cytotoxic T-cells and PD-L1+ cells compared to never- and former-smokers. While tumor mutation burden and mutant-allele tumor heterogeneity score do not associate with smoking status, gene-set enrichment analyses reveal significant suppression of IFN-α and IFN-γ response pathways in current smokers. Gene expression of canonical IFN-response chemokines of the CXCL9, CXCL10, CXCL11/CXCR3 axis are lower in current smokers than in former smokers suggesting decreased immune cell migration to the tumor site.
Conclusions
These results indicate that active tobacco use in HNSCC has an immunosuppressive effect through inhibition of tumor infiltration of cytotoxic T-cells likely as a result of suppression of IFN response pathways. Our study highlights the importance of understanding the interaction between smoking and TIM in light of emerging immune modulators for cancer management and the importance of smoking cessation during treatment with immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The James and Esther King Biomedical Research Grant.
Disclosure
C.H. Chung: Honoraria (self): bristol myers squibb; Honoraria (self): astrazeneca; Honoraria (self): Lilly; Honoraria (self): CUE Biopharma. J. Conejo-Garcia: Honoraria (self): Compass Therapeutics; Honoraria (self): Anixa Biosciences. R. Slebos: Spouse / Financial dependant: Bristol Myers Squibb; Spouse / Financial dependant: AstraZeneca ; Spouse / Financial dependant: CUE Biopharma; Spouse / Financial dependant: Lilly Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract